Fig. 2From: Impact on quality of life and safety of sublingual and subcutaneous immunotherapy in children with severe house dust mite and pollen-associated allergic rhinoconjunctivitisChanges in median Visual analogue and RQLQ scores with AIT. a Visual Analogue Score, b RQLQ score at baseline and annual intervals. Excludes patients who have discontinued. †P < 0.05 for Wilcoxon signed rank test between baseline and 1 year, or between 1- and 3-years scoresBack to article page